PE20141147A1 - Anticuerpos a pcsk9 y usos de los mismos - Google Patents
Anticuerpos a pcsk9 y usos de los mismosInfo
- Publication number
- PE20141147A1 PE20141147A1 PE2014000352A PE2014000352A PE20141147A1 PE 20141147 A1 PE20141147 A1 PE 20141147A1 PE 2014000352 A PE2014000352 A PE 2014000352A PE 2014000352 A PE2014000352 A PE 2014000352A PE 20141147 A1 PE20141147 A1 PE 20141147A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- pcsk9
- antibody
- refers
- amino acid
- Prior art date
Links
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 title abstract 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 title abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 108090000787 Subtilisin Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN ANTICUERPO, O FRAGMENTO DEL MISMO ENLAZANTE DEL ANTIGENO, CARACTERIZADO PORQUE COMPRENDE: a) UN REGION VARIABLE DE CADENA PESADA (HCVR), EN DONDE LA SECUENCIA DE AMINOACIDO DE HCDR1 SE PROPORCIONA POR LA SEC ID NO: 1, HCDR2 SE PROPORCIONA POR LA SEC ID NO: 2, HCDR3 SE PROPORCIONA POR LA SEC ID NO: 3; Y b) UNA REGION VARIABLE DE CADENA LIGERA (LCVR), EN DONDE LA SECUENCIA DE AMINOACIDO DE LCDR1 SE PROPORCIONA POR LA SEC ID NO 4, LCDR2 SE PROPORCIONA POR LA SEC ID NO:5, LCDR3 SE PROPORCIONA POR LA SEC ID NO: 6, EN DONDE DICHO ANTICUERPO SE UNE A CONVERTASA DE PROPROTEINA SUBTILISINA/QUEXINA TIPO 9 (PCSK9) HUMANA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE HIPERLIPIDEMIA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535625P | 2011-09-16 | 2011-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141147A1 true PE20141147A1 (es) | 2014-09-22 |
Family
ID=46881177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000352A PE20141147A1 (es) | 2011-09-16 | 2012-09-12 | Anticuerpos a pcsk9 y usos de los mismos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8530414B2 (es) |
| EP (1) | EP2756003A1 (es) |
| JP (1) | JP6013487B2 (es) |
| KR (1) | KR101607783B1 (es) |
| CN (1) | CN103781802B (es) |
| AP (1) | AP2014007499A0 (es) |
| AR (1) | AR087715A1 (es) |
| AU (1) | AU2012308786B2 (es) |
| BR (1) | BR112014005799A2 (es) |
| CA (1) | CA2845706C (es) |
| CL (1) | CL2014000590A1 (es) |
| CO (1) | CO6910164A2 (es) |
| CR (1) | CR20140087A (es) |
| DO (1) | DOP2014000041A (es) |
| EA (1) | EA024430B1 (es) |
| EC (1) | ECSP14013242A (es) |
| GT (1) | GT201400049A (es) |
| IL (1) | IL231282A0 (es) |
| MA (1) | MA35433B1 (es) |
| MX (1) | MX347475B (es) |
| MY (1) | MY168961A (es) |
| PE (1) | PE20141147A1 (es) |
| PH (1) | PH12014500576A1 (es) |
| SG (1) | SG2014014187A (es) |
| TN (1) | TN2014000094A1 (es) |
| TW (1) | TWI586687B (es) |
| UA (1) | UA114604C2 (es) |
| WO (1) | WO2013039958A1 (es) |
| ZA (1) | ZA201401267B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AU2012210481B2 (en) | 2011-01-28 | 2017-05-18 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to PCSK9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| WO2013039969A1 (en) | 2011-09-16 | 2013-03-21 | Regeneron Pharmaceuticals, Inc. | METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EP2810955A1 (en) | 2013-06-07 | 2014-12-10 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| CN111920954A (zh) | 2013-06-07 | 2020-11-13 | 再生元制药公司 | 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法 |
| EP2862877A1 (en) | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| WO2014209384A1 (en) | 2013-06-28 | 2014-12-31 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolema |
| CN106062003A (zh) | 2013-11-12 | 2016-10-26 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN105085684B (zh) * | 2014-05-14 | 2020-04-17 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| EP4328245A3 (en) | 2014-07-15 | 2024-06-05 | Kymab Ltd. | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| EP2975059A1 (en) | 2014-07-15 | 2016-01-20 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| DE202015009007U1 (de) | 2014-07-15 | 2016-08-19 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| KR20170123345A (ko) * | 2015-03-20 | 2017-11-07 | 오르후스 우니베르시테트 | 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제 |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
| CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
| RU2739208C2 (ru) * | 2015-12-31 | 2020-12-21 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение |
| JP2019509714A (ja) * | 2016-01-05 | 2019-04-11 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途 |
| KR102531889B1 (ko) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
| WO2018054240A1 (en) * | 2016-09-20 | 2018-03-29 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pcsk9 antibodies |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JOP20190112A1 (ar) | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| CN108424457B (zh) * | 2017-02-13 | 2021-06-01 | 成都金洛克锶生物技术有限公司 | 针对pcsk9抗体与检测试剂盒的制备及其用途 |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Ltd | peptídeo |
| AU2020209215B2 (en) | 2019-01-18 | 2023-02-02 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| JP2022532423A (ja) | 2019-05-17 | 2022-07-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 心血管系リスクを減らすためのゲノムに基づく方法 |
| CN114369164A (zh) * | 2020-10-15 | 2022-04-19 | 苏州君盟生物医药科技有限公司 | 抗pcsk9单克隆抗体的生产工艺 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1226243A2 (en) | 1999-10-22 | 2002-07-31 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules derived from rat brain and programmed cell death models |
| EP1309614A2 (en) | 2000-08-11 | 2003-05-14 | Eli Lilly And Company | Novel secreted proteins and their uses |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| EP2083860A4 (en) | 2006-11-07 | 2010-05-26 | Merck Sharp & Dohme | PCSK9 ANTAGONISTS |
| WO2008057459A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| US20100040611A1 (en) | 2006-11-07 | 2010-02-18 | Sparrow Carl P | Antagonists of pcsk9 |
| EP2106261A4 (en) | 2006-11-07 | 2010-05-26 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
| WO2008125623A2 (en) | 2007-04-13 | 2008-10-23 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| WO2009055783A2 (en) * | 2007-10-26 | 2009-04-30 | Schering Corporation | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| WO2009131740A2 (en) | 2008-04-23 | 2009-10-29 | Amgen Inc. | Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof |
| TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN102596249A (zh) | 2009-10-30 | 2012-07-18 | 默沙东公司 | Ax1和ax189 pcsk9拮抗剂和变体 |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| KR20150002894A (ko) | 2010-03-11 | 2015-01-07 | 리나트 뉴로사이언스 코프. | ｐＨ 의존성 항원 결합을 갖는 항체 |
-
2012
- 2012-08-29 AR ARP120103190A patent/AR087715A1/es unknown
- 2012-08-31 TW TW101131954A patent/TWI586687B/zh not_active IP Right Cessation
- 2012-09-12 MY MYPI2014700618A patent/MY168961A/en unknown
- 2012-09-12 WO PCT/US2012/054737 patent/WO2013039958A1/en not_active Ceased
- 2012-09-12 UA UAA201401793A patent/UA114604C2/uk unknown
- 2012-09-12 AP AP2014007499A patent/AP2014007499A0/xx unknown
- 2012-09-12 BR BR112014005799A patent/BR112014005799A2/pt active Search and Examination
- 2012-09-12 SG SG2014014187A patent/SG2014014187A/en unknown
- 2012-09-12 PE PE2014000352A patent/PE20141147A1/es not_active Application Discontinuation
- 2012-09-12 EA EA201490470A patent/EA024430B1/ru not_active IP Right Cessation
- 2012-09-12 CN CN201280044580.3A patent/CN103781802B/zh not_active Expired - Fee Related
- 2012-09-12 CA CA2845706A patent/CA2845706C/en not_active Expired - Fee Related
- 2012-09-12 US US13/611,196 patent/US8530414B2/en not_active Expired - Fee Related
- 2012-09-12 JP JP2014530744A patent/JP6013487B2/ja not_active Expired - Fee Related
- 2012-09-12 EP EP12761863.5A patent/EP2756003A1/en not_active Withdrawn
- 2012-09-12 AU AU2012308786A patent/AU2012308786B2/en not_active Ceased
- 2012-09-12 MX MX2014003175A patent/MX347475B/es active IP Right Grant
- 2012-09-12 PH PH1/2014/500576A patent/PH12014500576A1/en unknown
- 2012-09-12 KR KR1020147006577A patent/KR101607783B1/ko not_active Expired - Fee Related
-
2014
- 2014-02-19 ZA ZA2014/01267A patent/ZA201401267B/en unknown
- 2014-02-24 CR CR20140087A patent/CR20140087A/es unknown
- 2014-02-26 DO DO2014000041A patent/DOP2014000041A/es unknown
- 2014-03-03 IL IL231282A patent/IL231282A0/en unknown
- 2014-03-06 TN TNP2014000094A patent/TN2014000094A1/en unknown
- 2014-03-11 MA MA36818A patent/MA35433B1/fr unknown
- 2014-03-12 CL CL2014000590A patent/CL2014000590A1/es unknown
- 2014-03-13 EC ECSP14013242 patent/ECSP14013242A/es unknown
- 2014-03-13 GT GT201400049A patent/GT201400049A/es unknown
- 2014-03-14 CO CO14055604A patent/CO6910164A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| NZ603607A (en) | Cgrp antibodies | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| MX389805B (es) | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20150159A1 (es) | Composiciones y metodos para anticuerpos que actuan sobre el factor p | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |